HIK Hikma Pharmaceuticals Plc

RNS Number:1667F
Hikma Pharmaceuticals Plc
05 October 2007


                      Block Listing - Six Monthly Review

Name of Company:                          Hikma Pharmaceuticals PLC

Name of scheme:                           Hikma Pharmaceuticals PLC 2004 Stock
                                          Option Plan

Period of return:              From:      6 April 2007    To:    5 October 2007

Balance under block scheme:               1,719,400 ordinary shares of 10 pence
                                          each

The amount by which the block scheme has  Nil
been increased, if the scheme has been
increased since the date of the last
return:

Number of securities issued/allotted      314,000 ordinary shares of 10 pence 
under scheme during period:               each

Balance under scheme not yet issued/      1,405,400 ordinary shares of 10 pence
allotted at end of period                 each

Number and class of securities originally 166,537,951 ordinary shares of 10
listed and the date of admission          pence each originally listed on 1 
                                          November 2005
                                          
Total number of securities in issue at    169,451,407 ordinary shares of 10 
the end of the period                     pence each


                                    - ENDS -


Enquiries:

Hikma Pharmaceuticals PLC                               +44 20 7399 2760
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director

Notes to Editors


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products. Hikma's operates through three
businesses: "Branded", "Injectables" and "Generics", based principally in the
Middle East and North Africa ("MENA"), where it is a market leader and sells
across 18 countries, the United States and Europe. In 2006, Hikma achieved
revenues of $317 million (2005 $262 million) and profit attributable to
shareholders was $55 million (2005 $44 million). At 31 December 2006, the Group
had over 2,400 employees. For news and other information, please visit
www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BLREALELEDEXFFE

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024